TSVT stock icon

2seventy bio
TSVT

$3.72
1.06%
 

About: 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Employees: 425

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

22% more capital invested

Capital invested by funds: $206M [Q4 2023] → $251M (+$45.2M) [Q1 2024]

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

2% more funds holding

Funds holding: 113 [Q4 2023] → 115 (+2) [Q1 2024]

4.02% less ownership

Funds ownership: 95.18% [Q4 2023] → 91.17% (-4.02%) [Q1 2024]

43% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 46

44% less call options, than puts

Call options by funds: $707K | Put options by funds: $1.26M

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
34%
upside
Avg. target
$11.50
209%
upside
High target
$18
384%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Canaccord Genuity
John Newman
196%upside
$11
Buy
Maintained
9 May 2024
Citigroup
Samantha Semenkow
223%upside
$12
Buy
Maintained
8 Apr 2024
Wedbush
David Nierengarten
34%upside
$5
Neutral
Reiterated
18 Mar 2024
Leerink Partners
Daina Graybosch
384%upside
$18
Outperform
Upgraded
31 Jan 2024

Financial journalist opinion